Serve You Rx Adds 2 Stelara Biosimilars to Formulary to Help Patients Save Costs
In partnership with Cost Plus Drugs and Waltz Health, Serve You Rx has added Stelara biosimilars Otulfi and Yesintek to its formulary.
How the IRA Has Created a New Environment for Biosimilars
As IRA provisions are activated, the law’s impact on biologics and biosimilars will become more apparent. By using both the carrot and the stick, the IRA may finally bolster the market, increasing uptake of biosimilars to benefit patients and help lower costs.
presented by
A Path to Healing: Discovering Arizona’s PTSD Treatment Centers
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
What CVS Stands to Gain by Setting Up Biosimilar Subsidiary Cordavis
Pharmaceutical industry observers say CVS Health’s creation of Cordavis, a new biosimilar drugs company, is part of a strategy to make its move into this market as profitable as possible.
The Crucial Role of Medical Affairs in Bridging the Educational Gap Among Healthcare Professionals in Biosimilars
Biosimilars represent an important therapeutic option in modern healthcare, offering cost-effective alternatives to complex biological drugs. The educational gap among healthcare professionals poses a challenge to their widespread adoption. Medical Affairs teams in the pharmaceutical industry are at the forefront of bridging this gap
Three pharmacy trends that will define 2022
The pharmaceutical industry made more headlines in 2021 than in any other year in recent memory. And 2022 is set to be a monumental year as well.
Teva’s generic label not skinny enough to protect from $234M damages to GSK
When is a skinny label skinny enough to protect a generic drug from claims of patent infringement? The answer remains up to interpretation after an important, controversial decision from the Federal Circuit.
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
Sandoz loses challenge to patent on Amgen’s $5.2B autoimmune drug, may appeal to Supreme Court
A federal appeals court upheld two key patents covering Amgen's Enbrel, thus further preventing Novartis' generics unit from launching its biosimilar. However, an analyst wrote that the probability of Sandoz overturning the decision is low.
Navigating biosimilar reimbursement: Key challenges and steps to success
As the government has implemented step therapy in Medicare Advantage plans, and some commercial payers are preferring biosimilars, clarity around biosimilars and their reimbursement channels is paramount for providers and biosimilar pharmaceutical companies alike.
A short history of drug patent expirations
This eBook offers an overview of drug patents that were and are set to expire and highlights efforts by the FDA to stimulate the market for generics.
Merck to spin off drugs worth $6.5B into new company
The company, currently labeled only "NewCo," will focus on Merck's women's health, legacy products and biosimilars, while Merck itself focuses on oncology, vaccines, hospital drugs and animal health. The drugmaker's shares fell more than 4% when markets opened Wednesday.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
FDA, FTC look to crack down on tactics that they say thwart biosimilars
In a joint statement, FDA Commissioner Stephen Hahn and FTC Chairman Joseph Simons said they would look into anticompetitive practices like preventing biosimilar makers from obtaining product samples and misleading communications about biosimilars' safety and efficacy.
These drug patents are expected to expire in 2020
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
FDA hopes to spur insulin biosimilar development with easier clinical trial requirements
In a draft guidance, the agency proposed guidelines reducing the need for clinical trials to test insulin biosimilars for the potential to provoke immune system reactions. European regulators stopped recommending immunogenicity trials for insulin biosimilars in 2015.
Why is biosimilar adoption slow in the U.S., and can something be done to boost uptake?
Although the pathway for biosimilars has existed nearly a decade, adoption has lagged behind Europe. Interviewed experts pointed to physician education and the market's immaturity as significant factors.
USPTO agrees to Amgen’s petition to review Alexion’s patents on rare disease drug
Shares of Alexion fell more than 11 percent Friday as the office instituted an inter partes review for the drug, Soliris, in the blood disorder paroxysmal nocturnal hemoglobinuria.